Progyny Inc
NASDAQ:PGNY
Progyny Inc
In a world where the concept of family is continually evolving, Progyny Inc. emerges as a pioneer, reshaping the landscape of fertility and family-building benefits. Founded with a mission to offer comprehensive fertility solutions, the company leverages a unique combination of personalized concierge service and cutting-edge technology to meet the growing demand for reproductive health services. Progyny's role in the industry is substantial, providing a suite of tailored benefits that include fertility treatments, egg freezing, genetic testing, and support services. Through its proprietary Smart Cycle plan, Progyny stands apart by integrating these services into a single, streamlined benefits package, reducing complexities and elevating the experience for patients and employers alike.
The heart of Progyny's business model lies in its collaboration with employers, offering them the opportunity to include comprehensive fertility benefits as part of their health packages. By doing so, Progyny opens the door for companies to attract and retain talent in a competitive workforce, ensuring employees have access to vital reproductive assistance. The company generates revenue by partnering with these employers, who pay for the fertility benefits as part of their employee health plans. This innovative approach not only ensures recurring income for Progyny but also aligns the company’s success with positive health outcomes for its clients. As more organizations recognize the value in supporting employees' family-building journeys, Progyny’s influence and relevance in the market continue to grow, reinforcing its standing as a leader in fertility solutions.
In a world where the concept of family is continually evolving, Progyny Inc. emerges as a pioneer, reshaping the landscape of fertility and family-building benefits. Founded with a mission to offer comprehensive fertility solutions, the company leverages a unique combination of personalized concierge service and cutting-edge technology to meet the growing demand for reproductive health services. Progyny's role in the industry is substantial, providing a suite of tailored benefits that include fertility treatments, egg freezing, genetic testing, and support services. Through its proprietary Smart Cycle plan, Progyny stands apart by integrating these services into a single, streamlined benefits package, reducing complexities and elevating the experience for patients and employers alike.
The heart of Progyny's business model lies in its collaboration with employers, offering them the opportunity to include comprehensive fertility benefits as part of their health packages. By doing so, Progyny opens the door for companies to attract and retain talent in a competitive workforce, ensuring employees have access to vital reproductive assistance. The company generates revenue by partnering with these employers, who pay for the fertility benefits as part of their employee health plans. This innovative approach not only ensures recurring income for Progyny but also aligns the company’s success with positive health outcomes for its clients. As more organizations recognize the value in supporting employees' family-building journeys, Progyny’s influence and relevance in the market continue to grow, reinforcing its standing as a leader in fertility solutions.
Record Results: Progyny reported record revenue of $1.29 billion and adjusted EBITDA of $222 million for 2025, both up double digits over 2024 and well above initial guidance.
Strong Cash Flow: Operating cash flow hit a record $210 million, up 17% year-over-year, with over $50 million generated for three straight quarters.
Margin Expansion: Gross margin expanded by nearly 200 basis points over 2024, attributed to efficiencies and cost control.
Client Retention: Client retention remained near 100%, with growing relationships and no single client or industry driving a large revenue share.
Guidance Details: 2026 revenue is projected between $1.355–$1.405 billion (up 5.1–9% as reported, or 9.3–13.3% excluding a lost client), with adjusted EBITDA between $224–$239 million.
Membership Adjustment: Covered lives for 2026 are expected at 7.2 million, lower than prior estimates due to updated counts from existing clients, but not expected to affect utilization.
New Product Launch: Progyny Select, targeting the fully insured small employer market, will launch in 2026 but isn't expected to contribute materially until 2027.
